LogoLogo | Title 1Title 1 | Title 2Title 2 | PreclinicalPre | Phase IPh I | Phase IIPh II | Phase IIIPh III |
|---|---|---|---|---|---|---|
 | Patient Specific | Allo | Acute Myeloid Leukemia - MT-401 | |||
Auto | Lymphoma - MT-601 2022 IND | |||||
Pancreatic Cancer - MT-601 2022 IND | ||||||
OTF | Off-the-shelf | Acute Myeloid Leukemia - MT-401-OTS 1st patient 2023 | ||||
Lymphoma - MT-401-OTS | ||||||
Ovarian Cancer - MT-401-OTS | ||||||
Other | Other-sub | MT-1201 (12 antigens) | ||||
MT-401 Combination Therapies | ||||||
MT-601 Combination Therapies: peptide vaccine | ||||||
Solid Tumors Hematologic malignancy